<DOC>
	<DOCNO>NCT00352703</DOCNO>
	<brief_summary>This open-label , single-arm , multicentre study conduct Spain estimate effectiveness palifermin administer dose 60 mg/kg/day IV 3 consecutive day start condition regimen 3 consecutive day autologous PBSCT treat oral mucositis patient NHL MM receive high-dose conditioning chemotherapy .</brief_summary>
	<brief_title>PROMPT - Palifermin Reduction Oral Mucositis PBSC Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>NonHodgkin 's lymphoma ( NHL ) subject schedule receive BEAM conditioning chemotherapy follow autologous PBSCT , multiple myeloma ( MM ) subject schedule receive highdose Melphalan ( 200 mg/m2 ) conditioning chemotherapy , one twoday schedule , follow autologous PBSCT ≥Age 18 year ECOG performance status &lt; = 2 . In MM group , ECOG status &gt; 2 accept provide exclusively due MM ( e.g . pathological fracture ) Adequate pulmonary function measure correct carbon monoxide ( CO ) diffuse capacity ( DLCO ) ≥ 60 % predict Left ventricular ejection fraction ( LVEF ) ≥ 50 % Minimum 1.5 x 10^6 CD34+ cells/kg autologous transplantation Adequate haematological function ( ANC ≥ 1.5 x 10^9/L platelet count ≥ 100 x 10^9/L ) Serum creatinine &lt; = 2.0 mg/dL Total bilirubin &lt; = 2 mg/dL Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; = 4.0 x IULN Negative serum urine pregnancy test woman child bear potential within 14 day prior enrolment Each subject must give informed consent directly legally acceptable representative participating study specific procedure , receive study medication . History concurrent cancer NHL MM Prior treatment palifermin , keratinocyte growth factor ( eg , KGF2 ) Prior autologous allogeneic transplant Oral abnormality define baseline oral assessment WHO grade &gt; 0 Other investigational procedure exclude Subject currently enrol yet complete least 30 day since end investigational device drug study ( ) , subject receive investigational agent ( ) Subject childbearing potential evidently pregnant ( eg , positive HCG test ) breast feed Subject use adequate contraceptive precaution Known seropositive human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) Subject know sensitivity product administer dosing , include E coliderived product Subject previously treat study keratinocyte growth factor Unwilling unable complete patientreported outcome questionnaire Subject kind disorder compromise ability subject give write informed consent and/or comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Oral mucositis</keyword>
	<keyword>Non-Hodgkin 's lymphoma ( NHL )</keyword>
	<keyword>condition chemotherapy</keyword>
	<keyword>autologous PBSCT</keyword>
	<keyword>multiple myeloma ( MM )</keyword>
	<keyword>Melphalan</keyword>
</DOC>